Virtual Library

Start Your Search

Tunc Lacin



Author of

  • +

    P3.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 982)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.16-48 - Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer? (ID 12355)

      12:00 - 13:30  |  Author(s): Tunc Lacin

      • Abstract
      • Slides

      Background

      Positron emission tomography-computed tomography (PET / CT) is currently recommended to rule out metastatic disease in non-small cell lung cancer (NSCLC), even in early stage patients. In this study, our aim is to evaluate the effect of maximum value of standardized uptake values ​​(SUVmax) of primary tumor in PET/CT before surgery on relapse in operable NSCLC.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Data from 191 operable stage I-III NSCLC patients who had preoperative PET/CT was retrospectively analyzed between 2006-2018. Demografic and clinicopathologic findings were analyzed.Patients were staged according to TNM 8th edition. ROC curve analysis was performed to determine the ideal cut-off value of preoperative SUV max to predict relapse. The findings were analyzed using SPSS.

      4c3880bb027f159e801041b1021e88e8 Result

      At the time of diagnosis, median age was 62 years (39-82) and 84% of patients were male. Eighty-nine percent of our patients were smokers and smoking rate in males was 98%. Most common pathologic subtype was adenocarcinoma (Table 1). Mean follow-up duration was 35 months (1-128 months). Fourty-seven percent recurred and median progression free survival time (PFS) was 45 months (29-60 months). Median overall survival (OS) was 80 months.The ideal cut-off value of preoperative SUVmax that predicted relapse was 10.75 in the ROC analysis [AUC: 0,58 (0,50-0,66) p<0,05 with a sensitivity of 65%, and specificity of 57%]. Median PFS was 89 months in patients with preoperative SUVmax ≤ 10.75, and 34 months in patients with SUVmax > 10.75 (HR= 1.69; 95% CI 1.09-2.61; P =0.01).

      Table 1 Demographic and clinicopathological findings

      Gender

      Male

      160 (%84)

      Female

      31 (%16)

      Smoking

      Yes

      171(%89)

      No

      20 (%11)

      Stage

      Stage 1

      (n=51)

      Stage 1A1-A3

      33 (%17)

      Stage 1B

      18 ( %10)

      Stage 2

      (n=78)

      Stage 2A

      17 ( %8)

      Stage 2B

      61( %32)

      Stage 3

      (n=62)

      Stage 3A

      53(%28)

      Stage 3B

      9 (%5)

      Pathology Subtype

      Adenocarcinoma

      98 (%51)

      Squamous cell carcinoma

      81 (%42)

      Others

      12 (%7)

      Adjuvant treatment (n=123)

      Stage 1

      5 (%4)

      Stage 2

      65(%53)

      Stage 3

      53 (%43)

      Recurrences

      Yes

      90 (%47)

      No

      101 (%53)

      Recurrence patterns

      Local

      15 (16 %)

      Systemic

      75 (84 %)

      Status

      Alive

      131 (%69)

      Ex

      60 (%31)

      8eea62084ca7e541d918e823422bd82e Conclusion

      Approximately 30% of NSCLC patients are diagnosed at early stage. Although surgery is curative treatment in early stage, recurrences are common. Preoperative SUV(max) of primary tumor in PET/CT might be a predictor of postoperative relapse for operated NSCLC.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.